High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites

被引:54
|
作者
Ousley, Janet [1 ]
Niyibizi, Aline Aurore [1 ]
Wanjala, Stephen [1 ]
Vandenbulcke, Alexandra [1 ]
Kirubi, Beatrice [1 ]
Omwoyo, Willis [1 ]
Price, Janthimala [1 ]
Salumu, Leon [1 ]
Szumilin, Elisabeth [1 ]
Spiers, Sofie [2 ]
van Cutsem, Gilles [2 ]
Mashako, Maria [2 ]
Mangana, Freddy [2 ]
Moudarichirou, Ramzia [2 ]
Harrison, Rebecca [2 ]
Kalwangila, Tony [2 ]
Lumowo, Gisele [2 ]
Lambert, Vincent [2 ]
Maman, David [3 ]
机构
[1] Medecins Sans Frontieres, Paris, France
[2] Medecins Sans Frontieres, Brussels, Belgium
[3] Epicentre, Paris, France
基金
比尔及梅琳达.盖茨基金会;
关键词
Kenya; Democratic Republic of Congo; treatment failure; LIFE EXPECTANCY; MORTALITY; DISEASE; DEATH; ERA;
D O I
10.1093/cid/ciy103
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Human immunodeficiency virus (HIV) remains an important cause of hospitalization and death in low- and middle- income countries. Yet morbidity and in-hospital mortality patterns remain poorly characterized, with prior antiretroviral therapy (ART) exposure and treatment failure status largely unknown. Methods. We studied HIV-infected inpatients aged >= 13 years from cohorts in Kenya and the Democratic Republic of Congo (DRC), assessing clinical and demographic characteristics and hospitalization outcomes. Kenyan inpatients were prospectively enrolled during hospitalization; identical retrospective data were extracted for Congolese patients meeting the study criteria using routine medical information. Results. Among 338 HIV-infected patients in Kenya and 411 in DRC, 83.7% (95% confidence interval [CI], 79.4%-87.3%) and 97.3% (95% CI, 95.2%-98.5%), were admitted with advanced disease (defined as CD4 < 200 cells/mu L or World Health Organization stage 3/4 illness). Among inpatients with advanced HIV, 35.4% and 21.7% were ART-naive at admission. Patients under care had a median time of 44.1 (interquartile range [IQR], 18.4-90.5) months and 55.9 (IQR, 28.1-99.6) months on treatment; 17.2% (95% CI, 13.5%-21.6%) and 29.6% (95% CI, 25.4%-34.3%) died, 25.9% (95% CI, 16.0%-39.0%) and 22.5% (95% CI, 15.8%-31.0%) of these within 48 hours. Conclusions. Across 2 diverse clinical contexts in sub-Saharan Africa, advanced HIV inpatients were frequently admitted with low CD4 counts, often failing first-line ART. Earlier identification of treatment failure and rapid switching to second-line ART are needed.
引用
收藏
页码:S126 / S131
页数:6
相关论文
共 50 条
  • [21] Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality
    Brinkhof, Martin W. G.
    Boulle, Andrew
    Weigel, Ralf
    Messou, Eugene
    Mathers, Colin
    Orrell, Catherine
    Dabis, Francois
    Pascoe, Margaret
    Egger, Matthias
    PLOS MEDICINE, 2009, 6 (04)
  • [22] Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy
    Reid, SE
    Reid, CA
    Vermund, SH
    INTERNATIONAL JOURNAL OF STD & AIDS, 2004, 15 (11) : 713 - 716
  • [23] Availability of nutritional support services in HIV care and treatment sites in sub-Saharan African countries
    Anema, Aranka
    Zhang, Wendy
    Wu, Yingfeng
    Elul, Batya
    Weiser, Sheri D.
    Hogg, Robert S.
    Montaner, Julio S. G.
    El Sadr, Wafaa
    Nash, Denis
    PUBLIC HEALTH NUTRITION, 2012, 15 (05) : 938 - 947
  • [24] Bone health in women living with HIV in Sub-Saharan Africa: antiretroviral therapy, lactation, and menopause
    Nabwire, Florence
    JOURNAL OF BONE AND MINERAL RESEARCH, 2025,
  • [25] Pediatric Access and Continuity of HIV Care Before the Start of Antiretroviral Therapy in Sub-Saharan Africa
    Bastard, Mathieu
    Poulet, Elisabeth
    Nicolay, Nathalie
    Szumilin, Elisabeth
    Balkan, Suna
    Pujades-Rodriguez, Mar
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (09) : 981 - 986
  • [26] Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa?
    Zachariah, R.
    Harries, A. D.
    Philips, M.
    Arnould, L.
    Sabapathy, K.
    O'Brien, D. P.
    Ferreyra, C.
    Balkan, S.
    TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2010, 104 (06) : 387 - 391
  • [27] Cost of Differentiated HIV Antiretroviral Therapy Delivery Strategies in Sub-Saharan Africa: A Systematic Review
    Roberts, D. Allen
    Tan, Nicholas
    Limaye, Nishaant
    Irungu, Elizabeth
    Barnabas, Ruanne V.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 82 : S339 - S347
  • [28] Association between Antiretroviral Therapy and Cancers among Children Living with HIV in Sub-Saharan Africa
    Haq, Heather
    Elyanu, Peter
    Bulsara, Shaun
    Bacha, Jason M.
    Campbell, Liane R.
    El-Mallawany, Nader K.
    Keating, Elizabeth M.
    Kisitu, Grace P.
    Mehta, Parth S.
    Rees, Chris A.
    Slone, Jeremy S.
    Kekitiinwa, Adeodata R.
    Matshaba, Mogomotsi
    Mizwa, Michael B.
    Mwita, Lumumba
    Schutze, Gordon E.
    Wanless, Sebastian R.
    Scheurer, Michael E.
    Lubega, Joseph
    CANCERS, 2021, 13 (06) : 1 - 11
  • [29] Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes
    Haas, Andreas D.
    Zaniewski, Elizabeth
    Anderegg, Nanina
    Ford, Nathan
    Fox, Matthew P.
    Vinikoor, Michael
    Dabis, Francois
    Nash, Denis
    Sinayobye, Jean d'Amour
    Niyongabo, Theodore
    Tanon, Aristophane
    Poda, Armel
    Adedimeji, Adebola A.
    Edmonds, Andrew
    Davies, Mary-Ann
    Egger, Matthias
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [30] Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa
    Cooper, Curtis L.
    Mills, Edward
    Wabwire, Ben O.
    Ford, Nathan
    Olupot-Olupot, Peter
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2009, 13 (03) : 302 - 306